Dr Jagdish Chander Suri is one of the eminent Pulmonologist, Critical Care & Sleep Medicine expert with over 35 yrs of experience in this field. He was former Consultant, Professor and Head of Department of Pulmonary, Critical Care and Sleep Medicine at Vardhman Mahavir Medical C...
Dr Jagdish Chander Suri is one of the eminent Pulmonologist, Critical Care & Sleep Medicine expert with over 35 yrs of experience in this field. He was former Consultant, Professor and Head of Department of Pulmonary, Critical Care and Sleep Medicine at Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India. He is a recognized DM and MD post graduate guide for University of Delhi, GGS IP University, Delhi and National Board of Examination for the last 30 years. He is credited with introducing the field of clinical sleep medicine in India and established the first state of the art sleep lab of India at Safdarjang hospital in 1990. He also established the first critical care unit under Physician care exclusively in North India in 1990 and went on to establish the first comprehensive Department of Pulmonary, Critical Care and Sleep Medicine in India at Safdarjang Hospital. He started the DM program in Pulmonary and Critical Care Medicine at VMMC and Safdarjang Hospital, the second such centre in India to do so. As Vice principal of VMMC, he was instrumental in developing the course and curriculum for the MBBS students at GGS IP University.
Dr Suri has many contributions towards Govt. of India National programs where his aid started back in 1994 as an expert for the development of National TB Control Program.He is advisor for the development of guidelines for virus outbreaks such as H1N1, and COVID 19.Dr Suri has trained many leading Pulmonologists and Intensivists of India. He was actively involved as an expert in the development of guidelines for COPD, CPAP, BiPAP and Oxygen concentrator for the beneficiaries of Central Govt. Health Schemes. Dr Suri is also National advisor for the pulmonary group at the Drug Controller General India for the screening of new proposals of drug trials submitted by various pharmaceutical companies
Read More
Read Less